Nasdaq

Novavax to Participate in the Citi 12th Annual Biotech Conference

05-09-2017

GAITHERSBURG, Md., Sept. 05, 2017 (GLOBE NEWSWIRE) -- Novavax, Inc., (Nasdaq:NVAX) today announced the Company will participate in Citi's 12th Annual Biotech Conference.

Conference details are as follows:

Date: Thursday, September 7, 2017


Location: Mandarin Oriental hotel, Boston, MA

About Novavax

Novavax, Inc. (Nasdaq:NVAX) is a clinical-stage biotechnology company committed to delivering novel products to prevent a broad range of infectious diseases. Our recombinant nanoparticles and Matrix-M(TM) adjuvant technology are the foundation for groundbreaking innovation that improves global health through safe and effective vaccines. Additional information about Novavax is available on the Company's website, 
novavax.com
.

Contact: 




Investor Relations


Novavax, Inc.


Andrea N. Flynn, Ph.D.


Director, Investor Relations


ir@novavax.com


240-268-2000




Westwicke Partners


John Woolford


john.woolford@westwicke.com


443-213-0506




Media


Russo Partners, LLC


David Schull


Maggie Beller


david.schull@russopartnersllc.com


maggie.beller@russopartnersllc.com


212-845-4271



This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.

The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.

Source: Novavax, Inc. via GlobeNewswire

HUG#2131702